An agonistic anti‐Toll‐like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy

Immune‐checkpoint blockade antibodies have been approved for the treatment of cancer. However, poorly immunogenic tumours are less responsive to such therapies. Agonistic anti‐Toll‐like receptor 4 (TLR4) monoclonal antibodies (mAbs) activate only cell‐surface TLR4; in contrast, lipopolysaccharide (L...

Full description

Saved in:
Bibliographic Details
Published in:Immunology
Main Authors: Tsukamoto, Hiroki, Kubota, Kanae, Shichiku, Ayumi, Maekawa, Masamitsu, Mano, Nariyasu, Yagita, Hideo, Ohta, Shoichiro, Tomioka, Yoshihisa
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2019
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6742770/
https://ncbi.nlm.nih.gov/pubmed/31515801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imm.13095
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items